In a 45-year-old man with type 2 diabetes controlled (HbA1c 5.7%) on metformin extended‑release 750 mg daily, should the metformin dose be increased, and how should his untreated hypertension be managed?

Do Not Increase Metformin – Prioritize Hypertension Treatment and Consider Adding SGLT2i

With an HbA1c of 5.7%, this patient has achieved excellent glycemic control and does not require metformin dose escalation. The priority should be initiating treatment for his untreated hypertension, which poses a significantly greater cardiovascular risk than his well-controlled diabetes.

Glycemic Control Assessment

This patient's HbA1c of 5.7% is below the general target of <7% and even below the more stringent target of <6.5% 1. The American College of Physicians explicitly recommends deintensifying pharmacologic therapy when HbA1c falls below 6.5%, as no trials demonstrate clinical benefit from targeting levels this low, and treatment carries substantial harms including hypoglycemia, patient burden, and cost 1.

Why Not Increase Metformin?

• Current metformin dose (750 mg ER daily) is achieving target glycemic control
• Increasing metformin when HbA1c is already at 5.7% provides no additional cardiovascular or microvascular benefit 1
• Higher metformin doses (>2000 mg daily) offer minimal additional glucose-lowering efficacy while increasing gastrointestinal side effects 2
• The dose-response relationship shows diminishing returns above 1500-2000 mg daily 3, 4

Consider maintaining or even reducing the current metformin dose if the patient experiences any gastrointestinal symptoms, as the HbA1c is well below target 1.

The Critical Priority: Untreated Hypertension

The untreated hypertension represents a far greater cardiovascular risk than any marginal diabetes management adjustment. In patients with type 2 diabetes, hypertension is a major driver of cardiovascular disease, stroke, and chronic kidney disease 5.

Immediate Actions Required:

1. Obtain blood pressure measurements to confirm hypertension diagnosis and severity
2. Screen for chronic kidney disease with eGFR and urine albumin-to-creatinine ratio (ACR) – this should be done annually in all patients with type 2 diabetes 5
3. Assess for cardiovascular disease and other cardiovascular risk factors

Optimal Treatment Strategy

If Hypertension is Confirmed:

Start an ACE inhibitor or ARB as first-line antihypertensive therapy, particularly if albuminuria is present (ACR ≥30 mg/g) 5. This provides both blood pressure control and cardiovascular-renal protection.

Consider Adding SGLT2 Inhibitor:

Even with excellent glycemic control, adding an SGLT2 inhibitor with proven cardiovascular and renal benefits is strongly recommended for patients with type 2 diabetes who have:

• Hypertension (cardiovascular risk factor)
• eGFR ≥20 mL/min/1.73 m² 5

The 2022 KDIGO and ADA/KDIGO consensus statements recommend that most patients with type 2 diabetes and eGFR ≥30 mL/min/1.73 m² benefit from treatment with both metformin AND an SGLT2i 6, 5, 6. SGLT2 inhibitors provide:

• Cardiovascular mortality reduction
• Heart failure hospitalization reduction
• CKD progression reduction
• Blood pressure lowering (additional benefit for hypertension)
• No hypoglycemia risk when combined with metformin 2

This recommendation is independent of glycemic control needs – the cardiovascular and renal benefits occur even when glucose control is already adequate 5.

Statin Therapy:

Initiate moderate-intensity statin therapy for primary prevention of atherosclerotic cardiovascular disease, as recommended for all patients with type 2 diabetes and CKD 5.

Monitoring Plan

• Check eGFR and urine ACR before initiating SGLT2i and ACE inhibitor/ARB
• Monitor blood pressure regularly after starting antihypertensive therapy
• Continue annual screening for CKD (eGFR and ACR) 5
• Monitor vitamin B12 levels given metformin use (check at 2-3 year intervals or if anemia/neuropathy develops) 6
• Do not increase metformin dose unless HbA1c rises above 7% in the future

Common Pitfalls to Avoid

1. Therapeutic inertia on hypertension: Do not delay treating the hypertension while focusing solely on the well-controlled diabetes
2. Over-treating diabetes: Achieving HbA1c <6.5% with pharmacotherapy has no proven benefit and increases harm risk 1
3. Missing the opportunity for SGLT2i: These agents provide cardiovascular-renal protection beyond glucose lowering and should be considered even when glycemic control is excellent 5
4. Forgetting CKD screening: Annual screening is essential to guide medication choices and identify early kidney disease 5